<DOC>
	<DOCNO>NCT00298870</DOCNO>
	<brief_summary>The purpose study elucidate whether individualized medicine base NAT2 gene polymorphism could improve safety , efficacy economical benefit multi-drug therapy pulmonary tuberculosis isoniazid .</brief_summary>
	<brief_title>Randomized Trial Pharmacogenomics-based Tuberculosis Therapy ( RT-PGTT )</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>Newly diagnose pulmonary tuberculosis patient Informed consent include pharmacogenomic analysis Abnormal liver kidney function test treatment Longterm use steroid and/or immunodepressants Inadequate clinical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>pulmonary tuberculosis</keyword>
	<keyword>isoniazid</keyword>
	<keyword>arylamine N-acetyltransferase 2</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>genetic polymorphism</keyword>
	<keyword>individualized medicine</keyword>
	<keyword>drug-induced hepatotoxity</keyword>
</DOC>